<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B4645915-1B1F-4CE2-8D64-C4BC99865EFE"><gtr:id>B4645915-1B1F-4CE2-8D64-C4BC99865EFE</gtr:id><gtr:name>Transform Pharmaceuticals Inc</gtr:name><gtr:address><gtr:line1>29 Hartwell Avenue</gtr:line1><gtr:line4>Lexington</gtr:line4><gtr:line5>MA 02421</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE09B175-4199-4BDE-B719-27BE271395B0"><gtr:id>AE09B175-4199-4BDE-B719-27BE271395B0</gtr:id><gtr:name>Private Address</gtr:name><gtr:address><gtr:line1>Private Address</gtr:line1><gtr:line4>Private Address</gtr:line4><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9042D5A6-8830-497A-BE2D-3D1E355B3395"><gtr:id>9042D5A6-8830-497A-BE2D-3D1E355B3395</gtr:id><gtr:name>Pharmorphix Ltd</gtr:name><gtr:address><gtr:line1>250 Cambridge Science Park</gtr:line1><gtr:line2>Milton Road</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB4 0WE</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDC6C46B-0636-4A2F-8DEC-7E58056639FF"><gtr:id>BDC6C46B-0636-4A2F-8DEC-7E58056639FF</gtr:id><gtr:name>AVANTIUM TECHNOLOGIES B.V.</gtr:name><gtr:address><gtr:line1>PO Box 2915</gtr:line1><gtr:line2>1000 CX Amsterdam</gtr:line2><gtr:line3>The Netherlands</gtr:line3><gtr:line4>Amsterdam</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEE32133-0930-4A7B-A748-100346A885F1"><gtr:id>BEE32133-0930-4A7B-A748-100346A885F1</gtr:id><gtr:name>Cambridge Crystallographic Data Centre</gtr:name><gtr:address><gtr:line1>12 Union Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 1EZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD293334-DFCA-40C0-8441-A3BE6C7C33FF"><gtr:id>CD293334-DFCA-40C0-8441-A3BE6C7C33FF</gtr:id><gtr:name>Molecular Profiles Ltd</gtr:name><gtr:address><gtr:line1>1 Faraday Building  Nottingham Science &amp;</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 2QP</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C14FAF8A-52D7-49EA-82F9-E5A735A0D9B0"><gtr:id>C14FAF8A-52D7-49EA-82F9-E5A735A0D9B0</gtr:id><gtr:name>Johnson Matthey Plc</gtr:name><gtr:address><gtr:line1>40-42 Hatton Garden</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>EC1N 8EE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5728CD9E-C054-4345-8BE1-2541441351C3"><gtr:id>5728CD9E-C054-4345-8BE1-2541441351C3</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Florence</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F203A1BA-9A7A-46B0-A8CA-78391759727F"><gtr:id>F203A1BA-9A7A-46B0-A8CA-78391759727F</gtr:id><gtr:firstName>Sarah (Sally)</gtr:firstName><gtr:otherNames>Lois</gtr:otherNames><gtr:surname>Price</gtr:surname><gtr:orcidId>0000-0002-1230-7427</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72C55291-8869-4466-9573-9DE8CF113F73"><gtr:id>72C55291-8869-4466-9573-9DE8CF113F73</gtr:id><gtr:firstName>Derek</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>Tocher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FF03573X%2F1"><gtr:id>CF2B1C5C-9DD3-4238-8950-01EBA73CB5DD</gtr:id><gtr:title>Control and Prediction of the Organic Solid State: Translating the Technology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/F03573X/1</gtr:grantReference><gtr:abstractText>Many organic molecules can adopt more than one solid crystalline form, including polymorphs which differ only in the arrangement of the molecules. This can be exploited in the development of new speciality materials with optimised physical properties such as non-linear optical coefficients or molecular electronics, but it can prove disastrous for quality control when the new form appears unexpectedly during production or storage, as has occurred for some pharmaceuticals. However, the factors that control the diversity of possible solid forms are poorly understood. It has been said that the number of polymorphs of a molecule depends on the time and money spent looking for them. This is certainly a factor, when about 90% of systems studied for pharmaceutical companies are found to have multiple solid forms, and less than 5% of entries in the Cambridge Structural Database have two or more structures. The development of new organic materials and quality control in their manufacture requires a more scientific approach to understanding the possible range of crystal structures.The CPOSS project has been developing a computational method of predicting which crystal structures of a molecule are sufficiently low in energy that they might be able to form. We have also developed a workflow, including a uniquely powerful automated solvent crystallisation system, which is discovering many new crystalline forms even for the highly studied systems we used to validate the approach. By combining these results with other experimental and computer simulation work, the multi-disciplinary CPOSS team are developing a molecular level picture of what determines which of the computed low energy structures can be found experimentally for several specific molecules, ranging from the influence of solvent, to that of surfaces and even impurities. We even predicted possible new crystal structures of aspirin, paracetamol and piracetam before they were experimentally found! This Translation grant will enable the core of the CPOSS team to use the computational and experimental technologies they have developed in work with a broad range of collaborators on their particular organic solid state problems. These areas include molecular electronics and optical materials, energetic materials, pigments, agrochemicals and pharmaceuticals. Thus, we will develop methods of accurately computing which crystal structures are possible, and establish how to use the computed structures and experimental results to effectively determine which crystal structures might be found and the most efficient route to obtaining them. The CPOSS databases of known and hypothetical crystal structures and their properties, when covering a wide range of organic molecules, will provide a basic technology for polymorph prediction and control. This project will make available these complementary techniques to both academic and industrial organic solid state research scientists.</gtr:abstractText><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>946361</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750673</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon2020-FETOPEN</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>736899 MagnaPharm</gtr:fundingRef><gtr:id>3766A6A6-4F4C-42FF-B717-80538DA31F1E</gtr:id><gtr:outcomeId>58bef0f1eea2b1.37213048</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>720000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Scottish Funding Council</gtr:department><gtr:description>Scottish Funding Council</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Government of Scotland</gtr:fundingOrg><gtr:fundingRef>RKES-GS0280</gtr:fundingRef><gtr:id>2E4B2B08-C213-440D-98A1-33FE28C0BF9A</gtr:id><gtr:outcomeId>5ef271fc5ef27210</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>499000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K004670/1</gtr:fundingRef><gtr:id>AFA61618-2838-4EE0-A320-9DF0D4C4C756</gtr:id><gtr:outcomeId>5edbbf7a5edbbf8e</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fujifilm</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Fujifilm</gtr:fundingOrg><gtr:fundingRef>Strathclyde EPSRC KTA project EP/H50009X/1</gtr:fundingRef><gtr:id>68D10593-2D16-43B0-A43B-F3F7830CEC14</gtr:id><gtr:outcomeId>r-6767205332.18905806870e06</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5939782</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/I033459/1</gtr:fundingRef><gtr:id>5ACC3FF5-D33C-4F55-803C-5CA73F261BF4</gtr:id><gtr:outcomeId>5eda84e85eda84fc</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>142733</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ELI Lilly and Company</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:fundingRef>A PSR&amp;D Technology S Reutzel-Edens</gtr:fundingRef><gtr:id>53084D6D-DFB3-42C8-931D-BCF88E2F1176</gtr:id><gtr:outcomeId>r-1528698654.4064236068c0686</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Commonwealth Scholarship Commission</gtr:department><gtr:description>Commonwealth Scholarship</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>3C25E964-5A9D-4ED3-B5D0-DD5BF3A95383</gtr:id><gtr:outcomeId>54621a648089d0.17215561</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4348959</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K503289/1</gtr:fundingRef><gtr:id>F4A6B469-CA63-48E8-90C4-7B90F5F7222B</gtr:id><gtr:outcomeId>5edc87b65edc87ca</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GlaxoSmithKline (GSK)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:fundingRef>KT Secondments EP/H500278/1 UCL</gtr:fundingRef><gtr:id>DEC7C96B-145F-44A6-8953-C044CF66B1D7</gtr:id><gtr:outcomeId>5ec203465ec2035a</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Syngenta</gtr:description><gtr:fundingOrg>Syngenta</gtr:fundingOrg><gtr:fundingRef>Strathclyde EPSRC KTA project EP/H50009X/1</gtr:fundingRef><gtr:id>A8AFA0C6-3FA4-4CD7-90E4-89A4690BBA2B</gtr:id><gtr:outcomeId>5ec5029e5ec502b2</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79430</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>K504117/1</gtr:fundingRef><gtr:id>FB1CCF8F-64DD-4B11-8DD6-5B362F5A91E9</gtr:id><gtr:outcomeId>5edce7605edce774</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>297371</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Lilly Research Awards Program</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>2A111193-E48F-4792-838D-E1E011AF1480</gtr:id><gtr:outcomeId>5460d2e93679b1.21885332</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167578</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Eli Lilly Research Agreement</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>DB99017E-06F4-41CA-93C6-D7F2CF2134A2</gtr:id><gtr:outcomeId>56cb1f22b12f15.39877708</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>79217</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K504129/1</gtr:fundingRef><gtr:id>A1D7B7AD-B6FE-426C-9C34-EE792EF883C4</gtr:id><gtr:outcomeId>5edc8e785edc8e8c</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The methods developed have been used in industrial collaborations in conjunction with their screening results, resulting in some publications.</gtr:description><gtr:firstYearOfImpact>2011</gtr:firstYearOfImpact><gtr:id>8EA2B2F9-5A7F-4866-9273-E18F7A67CA27</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56cdbe6ab8a988.75911443</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have developed a computational method of predicting which crystal structures of a molecule are sufficiently low in energy that they might be able to form, and a uniquely powerful experimental workflow for identifying those that do. The combined multi-disciplinary approach can obtain a molecular level picture of what determines the range of possible outcomes of crystallisation of a molecule. During the Translation Grant, we have more than doubled, to over 170, the number of molecular systems whose computed crystal energy landscapes, the range of thermodynamically plausible crystal structures, are stored on our Crystal Navigator database. This includes a significant extension into multi-component systems, such as salts, cocrystals and hydrates of different stoichiometries, assessing the ability to determine which phase will form. There has been a qualitative change in the size and flexibility of molecule that can be tackled through algorithmic development, with a new program DMACRYS able to model crystals of much larger organic molecules. This allowed us to successfully predict the structure of a molecule more representative of modern pharmaceuticals in development, in the International Blind Test of Crystal Structure Prediction. 

The calculated crystal structure have complemented significant advances in our methodology for experimental investigations of the organic solid state. We have been able to characterise completely many microcrystalline powders, using the calculations to place the protons. We have learnt how to interpret the crystal energy landscape to suggest possible types of disorder, which can significantly affect the reproducibility of crystalline properties and reproducibility, and quantify when disorder is thermodynamically inevitable. The prediction of a propensity for forming a wide range of solvates is also possible, as seen in our studies of olanzapine yielding 56 solvates as well as 3 polymorphs. We are gaining confidence in determining which of the computed low energy structures may be found as metastable polymorphs, and our investigations of molecule/surface interactions show that heterosurfaces (designed, or from impurities) can produce new polymorphs that are not accessible by conventional experiments. We have used crystal energy landscapes to choose a templating experiment that produced the first crystal of the anti-epileptic, carbamazepine with catemeric hydrogen bonding, demonstrating that predicting crystal structures can lead to new polymorphs that would not otherwise be found.</gtr:description><gtr:exploitationPathways>The crystal energy landscapes can be used as a complementary technique as part of the pharmaceutical development process, not only to confirm that the most stable form is known, but also to suggest which other structures may be found as polymorphs and facilitate characterising these structures.

This information on the range of crystal packings of a molecule should allow a qualitative improvement in our ability to design organic solid state products and crystallisation processes suitable for their manufacture.
 This research has developed organic crystal structure software and experimental crystallisation and characterisation techniques, and algorithms for combining and interpreting the results, that can be applied to other organic molecules. These procedures have and continue to be disseminated into industry and academia.</gtr:exploitationPathways><gtr:id>21D0C95A-80B0-45DD-86CB-C15EEA5D4889</gtr:id><gtr:outcomeId>r-5838713958.709234775025f0</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.cposs.org.uk</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>DMACRYS - Energy minimisation package to simulate rigid molecules with multipoles
This package models crystals of rigid molecules, allowing lattice energy minimisation and the calculation of second derivative properties such as phonon frequencies and mechanical properties. It is designed to use anisotropic atom-atom model intermolecular potentials, particularly distributed multipole electrostatic models, but also has the capability of using distributed polarizabilities and anisotropic repulsion.</gtr:description><gtr:id>FA3E48F5-8ADF-4BD2-9F0E-0313A630C762</gtr:id><gtr:impact>The program is being licensed by UCL-B, and maintained and updated, with the 2014 release version being 2.0.8. There are licenses to industry and a large number of academic research groups throughout the world.</gtr:impact><gtr:outcomeId>5460c09d71e162.86068001</gtr:outcomeId><gtr:title>DMACRYS</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.cposs.org.uk/</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B14B9AA9-F0EE-42E2-B842-603C9DAB421B</gtr:id><gtr:title>A molecular picture of the problems in ensuring structural purity of tazofelone</gtr:title><gtr:parentPublicationTitle>Journal of Molecular Structure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad250d9bbc82445713c8f9906579e1dd"><gtr:id>ad250d9bbc82445713c8f9906579e1dd</gtr:id><gtr:otherNames>Price L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f36c49ed06.48603976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23246941-0B76-4BA1-BF15-21CAD759884B</gtr:id><gtr:title>The Amorphous Form of Salicylsalicylic Acid: Experimental Characterization and Computational Predictability</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f36d4e7ad1.51778186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46821409-D7EC-47F7-913E-A1278B09A94E</gtr:id><gtr:title>The unexpected but predictable tetrazole packing in flexible 1-benzyl-1H-tetrazole</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c6810bc24c5416cc1731b11428ae57"><gtr:id>79c6810bc24c5416cc1731b11428ae57</gtr:id><gtr:otherNames>Spencer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>54620593de3703.10505546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC4FE952-6AA6-40A4-8905-3621382F8C49</gtr:id><gtr:title>Computed crystal energy landscapes for understanding and predicting organic crystal structures and polymorphism.</gtr:title><gtr:parentPublicationTitle>Accounts of chemical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e5f37ff00e18caab7505774dc5042c6"><gtr:id>0e5f37ff00e18caab7505774dc5042c6</gtr:id><gtr:otherNames>Price SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-4842</gtr:issn><gtr:outcomeId>546208db90a0c8.48252066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47335744-F93B-45A5-B10F-15F2FBB59533</gtr:id><gtr:title>Complex Polymorphic System of Gallic Acid-Five Monohydrates, Three Anhydrates, and over 20 Solvates.</gtr:title><gtr:parentPublicationTitle>Crystal growth &amp; design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1528-7483</gtr:issn><gtr:outcomeId>54620593b81973.02250923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>357F1CEA-7338-4E51-93F8-B3328FB9B622</gtr:id><gtr:title>Analysis of the conformational profiles of fenamates shows route towards novel, higher accuracy, force-fields for pharmaceuticals.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e58de85ea9f0fbad199614bb804e9845"><gtr:id>e58de85ea9f0fbad199614bb804e9845</gtr:id><gtr:otherNames>Uzoh OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>56cb19d48c3c08.38473707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F0B9B90-F84B-4CE5-84F7-6AA65370F0EB</gtr:id><gtr:title>Can the Formation of Pharmaceutical Cocrystals Be Computationally Predicted? 2. Crystal Structure Prediction.</gtr:title><gtr:parentPublicationTitle>Journal of chemical theory and computation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31791c53ca3af1f056a26be51be77450"><gtr:id>31791c53ca3af1f056a26be51be77450</gtr:id><gtr:otherNames>Karamertzanis PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1549-9618</gtr:issn><gtr:outcomeId>54620a7c53aca2.11422907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F42423A3-3440-4899-A0DD-63C4BB5B5E89</gtr:id><gtr:title>Analysis of Enantiospecific and Diastereomeric Cocrystal Systems by Crystal Structure Prediction</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f36c9e0bb5.64713162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>390586D3-0C1F-4D67-82CB-67D19D72F3C4</gtr:id><gtr:title>A computationally inspired investigation of the solid forms of (R)-1-phenylethylammonium-(S)-2-phenylbutyrate.</gtr:title><gtr:parentPublicationTitle>Chirality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f348cd9a1623f6783955c801f7733cfa"><gtr:id>f348cd9a1623f6783955c801f7733cfa</gtr:id><gtr:otherNames>Antoniadis CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0899-0042</gtr:issn><gtr:outcomeId>54620680069231.92474538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AE5A3C5-26B9-440F-A3A0-C94CADF09BDB</gtr:id><gtr:title>Polymorphism in 2-Chlorobenzamide: Run of the Mill or Not?</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/269acca354b2d39187b6359369549d9e"><gtr:id>269acca354b2d39187b6359369549d9e</gtr:id><gtr:otherNames>Cockcroft J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d71189cb3e7.77947341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFFFECB0-D963-4CB4-8E02-678B5652B39E</gtr:id><gtr:title>Can the Formation of Pharmaceutical Cocrystals Be Computationally Predicted? I. Comparison of Lattice Energies</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66b485d62bf6e68205de6f3f732d00bd"><gtr:id>66b485d62bf6e68205de6f3f732d00bd</gtr:id><gtr:otherNames>Issa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>54620a7c7c93f1.91511247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E590A740-FDD7-4129-8CD3-9026E91C842B</gtr:id><gtr:title>Modelling organic crystal structures using distributed multipole and polarizability-based model intermolecular potentials.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb096212b874294029fca995fde4aa1"><gtr:id>cbb096212b874294029fca995fde4aa1</gtr:id><gtr:otherNames>Price SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>546206bb4860f8.13299093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDD2AC6E-07D6-4C4E-B6BB-1402CEB6B35D</gtr:id><gtr:title>Fifty-year old samples of progesterone demonstrate the complex role of synthetic impurities in stabilizing a metastable polymorph</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/120b938a96b670aa464558df7d59ecc2"><gtr:id>120b938a96b670aa464558df7d59ecc2</gtr:id><gtr:otherNames>Lancaster R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>5462067f3cac64.15542985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46BB512-2587-4408-A517-1A65C1211FB7</gtr:id><gtr:title>Are the Crystal Structures of Enantiopure and Racemic Mandelic Acids Determined by Kinetics or Thermodynamics?</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72bbe636c48d3c5ac1a91983efb04977"><gtr:id>72bbe636c48d3c5ac1a91983efb04977</gtr:id><gtr:otherNames>Hylton RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>5675e9d7bc2e6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE94294F-9EB0-40C8-A86C-156D3CB730B6</gtr:id><gtr:title>Predicting crystal structures of organic compounds.</gtr:title><gtr:parentPublicationTitle>Chemical Society reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb096212b874294029fca995fde4aa1"><gtr:id>cbb096212b874294029fca995fde4aa1</gtr:id><gtr:otherNames>Price SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-0012</gtr:issn><gtr:outcomeId>5461f36c770813.25860808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5572D1B-F4F6-4919-ADB8-22D22D7E1319</gtr:id><gtr:title>Crystal structure determination by combined synchrotronpowder X-ray diffraction and crystal structure prediction: 1 : 1 l-ephedrine
 
 -tartrate</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d32428cc153e7cee2d830d508f768769"><gtr:id>d32428cc153e7cee2d830d508f768769</gtr:id><gtr:otherNames>Wu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54620593941f06.09815332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDA90510-D104-4751-9940-D384EA69CBFD</gtr:id><gtr:title>Towards crystal structure prediction of complex organic compounds--a report on the fifth blind test.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section B, Structural science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f05ba58d16d165a353a09470c966d0a"><gtr:id>6f05ba58d16d165a353a09470c966d0a</gtr:id><gtr:otherNames>Bardwell DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0108-7681</gtr:issn><gtr:outcomeId>54620594cf64e7.84410978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3AFB653-4126-45B6-87B0-2D76DC0C3E3F</gtr:id><gtr:title>Substitutional and orientational disorder in organic crystals: a symmetry-adapted ensemble model.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>54620595291a26.62273330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EDD99F6-2795-48A2-B388-E84CA7CBCA1E</gtr:id><gtr:title>Carbamazepine Co-crystallization with Pyridine Carboxamides: Rationalization by Complementary Phase Diagrams and Crystal Energy Landscapes</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>doi_55f951951f761fa0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB33C6F-1454-42F9-AB40-1BDA87F6D5D7</gtr:id><gtr:title>Racemic Naproxen: A Multidisciplinary Structural and Thermodynamic Comparison with the Enantiopure Form</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4627965c982ddfdfb3c229f0eb25add"><gtr:id>c4627965c982ddfdfb3c229f0eb25add</gtr:id><gtr:otherNames>Braun D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>54620594a7de88.07108326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5117C052-AB4F-4266-B4E3-F2C4C509E447</gtr:id><gtr:title>Why don't we find more polymorphs?</gtr:title><gtr:parentPublicationTitle>Acta crystallographica Section B, Structural science, crystal engineering and materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb096212b874294029fca995fde4aa1"><gtr:id>cbb096212b874294029fca995fde4aa1</gtr:id><gtr:otherNames>Price SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2052-5192</gtr:issn><gtr:outcomeId>5461f36cf09b05.59707702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C01079A-6AA0-43BA-AE91-CF16056CA257</gtr:id><gtr:title>Salt or Cocrystal? A New Series of Crystal Structures Formed from Simple Pyridines and Carboxylic Acids</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c3d94000021a1dace42e7a459e45214"><gtr:id>0c3d94000021a1dace42e7a459e45214</gtr:id><gtr:otherNames>Mohamed S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>5462067fd74b12.62441347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93CCDD0B-22F4-4C11-B312-D4E853ED9788</gtr:id><gtr:title>Solution and nanoscale structure selection: implications for the crystal energy landscape of tetrolic acid.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>54620594342bc9.65013922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F9EB58E-69DA-4570-9027-D269A0756D70</gtr:id><gtr:title>Contrasting Polymorphism of Related Small Molecule Drugs Correlated and Guided by the Computed Crystal Energy Landscape</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4627965c982ddfdfb3c229f0eb25add"><gtr:id>c4627965c982ddfdfb3c229f0eb25add</gtr:id><gtr:otherNames>Braun D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f36c2084f2.16749626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7366C5FE-2F83-4664-8ABC-A4E09EDE9DC3</gtr:id><gtr:title>Computational prediction of salt and cocrystal structures--does a proton position matter?</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c3d94000021a1dace42e7a459e45214"><gtr:id>0c3d94000021a1dace42e7a459e45214</gtr:id><gtr:otherNames>Mohamed S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>54620595763f55.95545331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC93734-A772-4FC2-A303-644A6271E176</gtr:id><gtr:title>Report on the sixth blind test of organic crystal structure prediction methods.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica Section B, Structural science, crystal engineering and materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ae18d41adec0f0acf88f4e99caecbc9"><gtr:id>9ae18d41adec0f0acf88f4e99caecbc9</gtr:id><gtr:otherNames>Reilly AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2052-5192</gtr:issn><gtr:outcomeId>585d5bac3a26f8.14001476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C349C012-D3D0-449C-8BBE-C7F6152342E6</gtr:id><gtr:title>Evaluating a Crystal Energy Landscape in the Context of Industrial Polymorph Screening</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f044b5a4dfece3d0e575327c61924a4a"><gtr:id>f044b5a4dfece3d0e575327c61924a4a</gtr:id><gtr:otherNames>Ismail S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f36d254be2.03046075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E179CB3-5F41-48F2-9DE0-8961E942A5A9</gtr:id><gtr:title>A strategy for producing predicted polymorphs: catemeric carbamazepine form V.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cd27ede4e5efa368803e9d8fe11c0cc"><gtr:id>9cd27ede4e5efa368803e9d8fe11c0cc</gtr:id><gtr:otherNames>Arlin JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5461f36bb10c75.39735177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9B11644-0A74-4334-8532-F1E0589A46BC</gtr:id><gtr:title>The potential of computed crystal energy landscapes to aid solid-form development.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb096212b874294029fca995fde4aa1"><gtr:id>cbb096212b874294029fca995fde4aa1</gtr:id><gtr:otherNames>Price SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>585d652beed2c9.39599137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C635E9C7-C523-4F12-A502-12023B5BDEAA</gtr:id><gtr:title>The crystal structures of chloro and methyl ortho-benzoic acids and their co-crystal: rationalizing similarities and differences</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d4442b3e03ac3c690fa78d35f93a4b2"><gtr:id>9d4442b3e03ac3c690fa78d35f93a4b2</gtr:id><gtr:otherNames>Polito M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>54620a7ca6a7e1.86610858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CEDBFE6-925E-42EC-8E8A-B2AEAD45FF2D</gtr:id><gtr:title>Solid-State Forms of ?-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?</gtr:title><gtr:parentPublicationTitle>Crystal growth &amp; design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1528-7483</gtr:issn><gtr:outcomeId>5462067f6304c4.94942006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C533568-E8E5-4CC8-A2ED-9B709605B613</gtr:id><gtr:title>Successful prediction of a model pharmaceutical in the fifth blind test of crystal structure prediction.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9259070c55e2629b081b1dec7b479020"><gtr:id>9259070c55e2629b081b1dec7b479020</gtr:id><gtr:otherNames>Kazantsev AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>546205954d6ef9.55382248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09CA9F33-F433-4799-AD68-1A4D57B4B73B</gtr:id><gtr:title>Spontaneous Resolution of Enantiomers by Crystallization: Insights from Computed Crystal Energy Landscapes</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78d4970487681cfa09286f752c85307c"><gtr:id>78d4970487681cfa09286f752c85307c</gtr:id><gtr:otherNames>D'Oria E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>5462067f8a40a2.60961003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54FC031D-3A0C-43B9-8488-DD2F086A87BD</gtr:id><gtr:title>The complexity of hydration of phloroglucinol: a comprehensive structural and thermodynamic characterization.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>546205945bc373.20819790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8DA50C1-54EA-45CA-8741-0B4AA691DE03</gtr:id><gtr:title>Screening for cocrystals of succinic acid and 4-aminobenzoic acid</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66b485d62bf6e68205de6f3f732d00bd"><gtr:id>66b485d62bf6e68205de6f3f732d00bd</gtr:id><gtr:otherNames>Issa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>54620594833690.83199474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CDB5FA6-6E6D-4B85-894E-A950CF104200</gtr:id><gtr:title>Which, if any, hydrates will crystallise? Predicting hydrate formation of two dihydroxybenzoic acids.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>546205959abc90.35145071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B599B3F6-F2A1-4FAC-B911-60DF263DB3E7</gtr:id><gtr:title>A predicted dimer-based polymorph of 10,11-dihydrocarbamazepine (Form IV)</gtr:title><gtr:parentPublicationTitle>CrystEngComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90576d608ab0c7e78238cac8f2fcd95b"><gtr:id>90576d608ab0c7e78238cac8f2fcd95b</gtr:id><gtr:otherNames>Arlin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>5462067fb085f8.12284528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A5C4533-E805-4556-8C31-16260810E255</gtr:id><gtr:title>Navigating the Waters of Unconventional Crystalline Hydrates.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn><gtr:outcomeId>56cb18b1b643a4.34780807</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B4A7E1B-D017-447F-B485-374B946CF46D</gtr:id><gtr:title>Polymorphism Arising from Differing Rates of Compression of Liquids</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74d4a90a8cf2d2586c1a036a06f08e6b"><gtr:id>74d4a90a8cf2d2586c1a036a06f08e6b</gtr:id><gtr:otherNames>Ridout J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461f36beb9190.89059958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00A39178-50D9-4B12-9CA0-E6A5F0FC197F</gtr:id><gtr:title>Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6438b8f63e0ba08da34d6631fd19a5a7"><gtr:id>6438b8f63e0ba08da34d6631fd19a5a7</gtr:id><gtr:otherNames>Bhardwaj R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5461f36d75e6a1.16601093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EDD90D8-77AA-4717-849E-B390B9335A26</gtr:id><gtr:title>Form II Caffeine: A Case Study for Confirming and Predicting Disorder in Organic Crystals</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98edfe11e3949c321ce664f4d0e6111"><gtr:id>f98edfe11e3949c321ce664f4d0e6111</gtr:id><gtr:otherNames>Habgood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>54620594f33a84.02185148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90148348-5F62-46D3-8B8F-822B25DE3A3C</gtr:id><gtr:title>Is the Fenamate Group a Polymorphophore? Contrasting the Crystal Energy Landscapes of Fenamic and Tolfenamic Acids</gtr:title><gtr:parentPublicationTitle>Crystal Growth &amp; Design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dda147126abe1be394784fa242dabaa"><gtr:id>7dda147126abe1be394784fa242dabaa</gtr:id><gtr:otherNames>Uzoh O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>546205941032e7.35654811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F99A3E6-1502-4BB3-920E-9B2C9C250B17</gtr:id><gtr:title>Can computed crystal energy landscapes help understand pharmaceutical solids?</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbb096212b874294029fca995fde4aa1"><gtr:id>cbb096212b874294029fca995fde4aa1</gtr:id><gtr:otherNames>Price SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>585d7d0eba4082.78657110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D075743C-CFED-4DB4-8126-0C13BA6A0711</gtr:id><gtr:title>Absorbing a Little Water: The Structural, Thermodynamic, and Kinetic Relationship between Pyrogallol and Its Tetarto-Hydrate.</gtr:title><gtr:parentPublicationTitle>Crystal growth &amp; design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4fb1512a2fac25e183bfded75dfc8f"><gtr:id>6c4fb1512a2fac25e183bfded75dfc8f</gtr:id><gtr:otherNames>Braun DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1528-7483</gtr:issn><gtr:outcomeId>5461f36cca8f46.41893942</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/F03573X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>863FC58A-7217-42EA-B076-663F2D770BB8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical measurement</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>1820CCC5-B4C4-47E9-B81F-8F49AC606F0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical Structure</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>561091A1-9FC9-4508-B1B2-2F3623E1FC9D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Materials Characterisation</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>